Recent Articles

November 2, 2015 9:55 am
Craig Morgan, director at goBalto Inc.
The drug development process is long, arduous, and costly, driving many sponsors to consider greater use of contract research organizations (CROs). This move reflects sponsors’ sharper focus on core competencies and the shifting of management and conducting of clinical trials to CROs. Read more...
October 29, 2015 8:30 am
Cynthia Fox, Science Editor
A prominent editorial, finding breast cancers arose in the massive 16,000-patient Women’s Health Initiative (WHI) study due to “progesterone,” is outright wrong, wrote a top gynecologist and a top oncologist in a recent JAMA Oncology. Read more....
October 28, 2015 8:30 am
Mary F. Lopez, Bryan Krastins, Gregory Byram, Maryann Vogelsang, Gouri Vadali; at Nuclea Biotechnologies
Mass spectrometry (MS) is revolutionizing the way that biomarkers are detected and quantified, with proven application in clinical laboratories in toxicology, endocrinology, and biochemical genetics. The detection of parathyroid hormone, (PTH) in human blood is a new case in point. Read more...
October 27, 2015 8:30 am
Meg Snyder, Editor, Pharmaceutical Processing
Today’s pharmaceutical market is growing exponentially in potential. Not only has there been new brand-name and generic drugs produced for a myriad of medical conditions, but also the arrival of biosimilars in the United States. All of these changes only serve to engender a competitive environment, thriving on quantitative and qualitative productivity and rapidity, among manufacturers. Read more...
October 26, 2015 9:06 am
Holly Hilton, Ph.D., Director, Biomarkers and Translational Sciences, PPD Laboratories; Gregory J. Dennis, M.D., Therapeutic Area Head, Immunoinflammation, PPD
In an ideal scenario, a biomarker would both reveal the driver of disease and identify an effective treatment. However, biomarkers are necessarily based on the pathobiology of the underlying disease and therefore for most diseases must be used to advance drug development and patient care in a more sequential fashion. Read more...
October 20, 2015 8:30 am
​ George Karlin-Neumann, Digital Biology Center, Bio-Rad Laboratories, Inc.
Liquid biopsy represents an attractive non-invasive way to monitor cancer progression and response (e.g. resistance) to treatments. The ultimate goal of physicians and clinicians is to use this approach to screen asymptomatic patients for the disease. As companies enter the estimated multibillion-dollar liquid biopsy market, one important question has yet to be addressed: Are such tests clinically useful? Read more...
October 19, 2015 8:30 am
Ralf Huss, MD, Chief Medical Officer, Definiens
Immunotherapy is touted more and more as the future of cancer treatment. Big pharma is determinedly looking for alternative therapeutics beyond chemotherapy, which has not shown to provide convincing benefit with solid tumors, and immunotherapies provide a good option as we learn more about the mechanisms of action and how they impact the immune system. Read more...
October 12, 2015 4:52 pm
Stephanie Guzowski, Editor
Eli Lilly announced on Friday plans to expand its presence in New York City, with an addition of 30,000 square feet of space and about 50 new jobs to its R&D site at the Alexandria Center for Life Science.
October 6, 2015 10:23 am
Laura McKain, M.D., Medical Director, Pharmacovigilance; Tammy Jackson, Director, Preclarus Development, Clinical Innovation; Cindy Elko-Simms, M.D., Vice President, Pharmacovigilance, of PPD
Pharmaceutical companies must continuously monitor the safety of investigational products in development for adverse events that may be unexpected, occur at an increased frequency or severity, or result in an unexpected outcome. Ongoing safety signal detection leads to optimal patient protection and is essential to obtaining regulatory approval. Read more...
October 2, 2015 10:00 am
Cynthia Fox, Science Editor
Two JAMA studies on female scientists and bias are eliciting stunned reactions. One JAMA study, which found women launching labs receive almost three times less funding than men,was “totally shocking” to Massachusetts Institute of Technology (MIT) emeritus professor Nancy Hopkins, M.D., she told Drug Discovery & Development.  Hopkins was uninvolved in that study. Read more...
Subscribe to Drug Discovery & Development